A DISPROPORTIONALITY ANALYSIS OF THE SERIOUS ADVERSE DRUG EVENTS ASSOCIATED WITH GENE THERAPY PRODUCTS USING THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

被引：0
|
作者：
Ghanem, B. [1 ]
Fleming, M. [2 ]
Brown, L. M. [1 ]
Rodriguez-Monguio, R. [1 ]
Seoane-Vazquez, E. [1 ]
机构：
[1] Chapman Univ, Sch Pharm, Irvine, CA USA
[2] Univ North Texas Hlth Sci Ctr, Irvine, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR148
引用
收藏
页码：S237 / S237
页数：1
相关论文
共 50 条
  • [1] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    [J]. BMC Pharmacology and Toxicology, 24
  • [2] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [3] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [4] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Rees, Kate E.
    Chyou, Te-yuan
    Nishtala, Prasad S.
    [J]. DRUG SAFETY, 2020, 43 (06) : 607 - 609
  • [5] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Kate E. Rees
    Te-yuan Chyou
    Prasad S. Nishtala
    [J]. Drug Safety, 2020, 43 : 607 - 609
  • [6] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Dai, Zhicheng
    Zhang, Jiafeng
    Tao, Zhengbo
    Gao, Rui
    Zhao, Qinghua
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [8] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    [J]. HELIYON, 2024, 10 (17)
  • [9] Bleeding related adverse events associated with antiviral treatment in influenza patients: A disproportionality analysis using FDA adverse event reporting system (FAERS)
    Sarker, Jyotirmoy
    Carkovic, Emir
    Lee, Todd A.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 486 - 487
  • [10] Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
    Shu, Yamin
    Ding, Yiling
    Liu, Lulu
    Zhang, Qilin
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2705 - 2716
12345